Search icon
TCS, HDFCBANK, SBI Liquid Fund (G)
Suraksha Diagnostic Ltd.

SURAKSHA

Equity

BSE,NSE

Min. Investment

4,20,000.00

Open a free Demat account and invest in IPOs easily.

Download Orca

Google PlayApp Store

To access realtime data for GP Eco Solutions India Ltd. and use advance features for Applying IPO. Register or Login to Orca.

IPO Details

Bidding Dates

29 Nov 24 - 03 Dec 24

Price Range ₹

420 - 441

Total Equity

592.37Cr

Lot Size

34

Exchange Status

BSE,NSE

IPO Doc

Subscription Rate

Non-Institutional Investor

0.95×

Qualified Institutional Buyers

1.74×

Employees

0.00×

Retail Investors

0.95×

Total subscription Rate

1.27×

IPO Timeline

Offer start

29 Nov 2024

Offer end

03 Dec 2024

Allotment

04 Dec 2024

Refund initiation

05 Dec 2024

Demat transfer

05 Dec 2024

Listing

06 Dec 2024

About Company

Incorporated in 2005, Suraksha Diagnostic Limited specializes in pathology, radiology testing, and medical consultancy services. The company operates a central reference laboratory supported by 8 satellite laboratories and 215 customer touchpoints, including 49 diagnostic centers and 166 sample collection centers, as of June 30, 2024. These facilities span across West Bengal, Bihar, Assam, and Meghalaya. Suraksha Diagnostic Limited provides both online and offline medical consultation services through 44 diagnostic centers, which also host 120 polyclinics with a network of over 750 doctors. The company’s diagnostic operations are powered by advanced technology systems, including a Laboratory Information Management System (LIMS), an integrated Radiology Information System (RIS), a Picture Archive Communication System (PACS), and an Enterprise Resource Planning System (ERP), ensuring seamless and efficient processes. Additionally, the company offers vaccination services and tailored testing packages for disease prediction and early detection. Leveraging digital pathology and artificial intelligence, it enhances the accuracy and efficiency of blood testing. Radiology reporting is managed entirely through a digital platform, enabling faster case processing and reducing turnaround times across all diagnostic centers.

Year Founded

15-03-2005

Promotor Details

Somnath Chatterjee

Promoter Holdings Details

ParticularPre-IPOPost-IPO
Percentage61.0748.78
Share Capital3180203425405590

Offer to Public

1,34,32,533.00 Cr

Project Details

  • None - Nonecr

Highlights

  • Suraksha Diagnostic Limited holds a leading position in the diagnostic market of eastern India, with significant growth potential in a fragmented industry.
  • The company provides a wide range of diagnostic services, including pathology, radiology, and medical consultations, catering to diverse healthcare needs under one roof.
  • Equipped with cutting-edge technology, such as LIMS, RIS, PACS, and ERP systems, and supported by skilled professionals, the company ensures accurate and reliable diagnostic services.
  • Suraksha Diagnostic is a trusted name in the healthcare industry, known for its commitment to quality and customer-centric services.
  • The company prioritizes personalized care, offering vaccination services and customized testing packages for early disease detection and prevention, further enhancing customer loyalty.

Challenges

  • The company heavily relies on West Bengal for its business, making it vulnerable to regional disruptions that could significantly impact overall performance.
  • Staying updated with new diagnostic tests and technologies is critical, and any delays in adoption could weaken the company’s competitive position.
  • The reliance on third-party vendors for testing equipment makes the company susceptible to supply chain disruptions, which could hinder operations.
  • Many sample collection centers are franchise-operated, and failure to maintain consistent quality standards could harm the company’s reputation and service reliability.
  • Intense competition in the diagnostics industry may lead to price reductions, potentially impacting profit margins and overall financial performance.

Financials

YearsTotal AssetsShare CapitalProfit After TaxConsolidated Net ProfitAdjusted EPS
202220,071.72852.86643.51643.5193.2623
20201,72,87,48,300.008,52,85,900.00231.27236.26342.4058
20243,002.0785.295,49,89,260.005,49,89,260.0079.6946
202117,104.73852.86643.51643.5193.2623
20232,811.9585.29231.27236.26342.4058
Enrich money logo